Breast Cancer Biology and Treatment

Breast cancer is a malignant neoplasm of the breast and one of the most commonly diagnosed cancers worldwide. It is not a single disease but a family of molecular subtypes defined by hormone-receptor and HER2 status, which shape prognosis and treatment. The interplay of tumor biology, staging, and subtype-directed therapy is the organizing theme of breast oncology.

Definition

Breast cancer is a malignant tumor arising from breast epithelium, classified by histology and by receptor status (estrogen and progesterone receptors and HER2), with these markers defining clinically meaningful molecular subtypes that guide therapy.

Scope

This topic covers the molecular classification of breast cancer (hormone-receptor and HER2 status, intrinsic subtypes), its epidemiology, the role of screening, and the principles of subtype-directed systemic therapy and local treatment. It is a reference overview of the biology and treatment framework and of how the evidence base is structured, not individualized clinical advice.

Core questions

• How do hormone-receptor and HER2 status define breast cancer subtypes?
• Why is breast cancer best understood as several biologically distinct diseases?
• How does subtype determine the choice of endocrine, anti-HER2, or chemotherapy approaches?
• What is the evidence basis for mammographic screening and its trade-offs?

Key concepts

• Hormone-receptor (ER/PR) status
• HER2 status and HER2-targeted therapy
• Intrinsic molecular subtypes (luminal A/B, HER2-enriched, basal-like)
• Triple-negative breast cancer
• Endocrine therapy
• Mammographic screening
• TNM staging of the breast

Mechanisms

Breast cancers differ in the signaling pathways that drive them. Gene-expression profiling revealed intrinsic molecular subtypes that correspond broadly to clinical markers: hormone-receptor-positive tumors depend on estrogen signaling and respond to endocrine therapy, HER2-positive tumors are driven by HER2 amplification and respond to HER2-directed agents, and triple-negative tumors lack these targets (Perou et al., 2000; Harbeck & Gnant, 2017). The demonstration that adding the anti-HER2 antibody trastuzumab to adjuvant chemotherapy improves outcomes in HER2-positive disease was a landmark proof that subtype-directed therapy changes the natural history of the disease (Romond et al., 2005).

Clinical relevance

Breast cancer is a paradigm for how molecular subtyping turns one anatomic site into several distinct diseases with different prognoses, predictive biomarkers, and treatment frameworks. This entry describes that biology and the structure of its evidence; it does not provide individualized diagnostic or treatment recommendations.

Epidemiology

Breast cancer is among the most frequently diagnosed cancers worldwide and a leading cause of cancer death in women, with incidence varying by region, reproductive and hormonal factors, and screening practices (Bray et al., 2024). Established risk factors include age, family history and inherited susceptibility, and hormonal exposures; mortality has declined in many settings with earlier detection and improved systemic therapy (Loibl et al., 2021).

Evidence & guidelines

Randomized evidence underpins subtype-directed treatment, including endocrine therapy for hormone-receptor-positive disease and HER2-directed therapy for HER2-positive disease (Romond et al., 2005). Population mammographic screening reduces breast-cancer mortality in appropriate age groups while carrying recognized harms such as false positives and overdiagnosis, and guideline bodies differ on optimal age ranges and intervals. Contemporary guidelines integrate molecular subtype, stage, and risk; specifics evolve and should be read in current sources (Harbeck & Gnant, 2017; Loibl et al., 2021).

History

Breast cancer treatment evolved from radical surgery toward breast-conserving approaches combined with radiotherapy and systemic therapy. The recognition of estrogen-receptor dependence established endocrine therapy, and gene-expression studies around 2000 defined intrinsic molecular subtypes (Perou et al., 2000). The subsequent success of HER2-targeted therapy confirmed that molecular subtype, not anatomy alone, governs treatment, ushering in the modern biomarker-driven era.

Debates

Optimal age range and interval for mammographic screening

Screening reduces breast-cancer mortality but causes false positives and overdiagnosis, and guideline bodies disagree on the best starting age and frequency, reflecting differing weightings of benefits and harms.

Seminal works

• perou-2000
• romond-2005
• harbeck-2017
• loibl-2021

Frequently asked questions

Why is breast cancer described as several different diseases?

Tumors differ by hormone-receptor and HER2 status, which define molecular subtypes with distinct biology, prognosis, and treatment; this is why one anatomic site is managed as several biologically distinct entities.

What does HER2-positive breast cancer mean?

It refers to tumors with amplification or overexpression of the HER2 protein, which drives growth and can be targeted with HER2-directed agents; this subtype is identified by testing and treated differently from HER2-negative disease.